Adagio Therapeutics Inc Aktie News

NEW HAVEN, Conn., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced it has received and is aligned with advice from the U.S. Food and Drug Administration (FDA) on the LIBERTY Phase 3 clinical trial, which will assess the safety and immunologic profile of VYD2311, the company's vaccine- alternative monoclonal antibody investigational candidate for the prevention of C...

NEW HAVEN, Conn., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) and the SPEAR Study Group today announced the plan to initiate a Phase 2 clinical trial evaluating monoclonal antibody VYD2311 in individuals with Long COVID or COVID vaccine injury.

NEW HAVEN, Conn., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced preliminary fourth quarter (Q4) revenue and recent business highlights.

NEW HAVEN, Conn., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for VYD2311, an investigational vaccine-alternative monoclonal antibody candidate for the prevention of COVID.

NEW HAVEN, Conn., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced initiation of the DECLARATION trial evaluating VYD2311, an investigational vaccine-alternative monoclonal antibody candidate for the prevention of COVID. DECLARATION is the company's Biologics License Application (BLA)-enabling, Phase 3 randomized, triple-blind, placebo-controlled clinical trial to ...

NEW HAVEN, Conn., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that management will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Tuesday, December 2, 2025, at 2:35 p.m. ET in Miami, FL.

NEW HAVEN, Conn., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced it has identified and nominated for preclinical development a potentially best-in-class monoclonal antibody candidate for the prevention of Respiratory Syncytial Virus (RSV) among neonates, infants, and children. Invivyd's investigational antibody, VBY329, was generated by Invivyd's proprietary anti...

Invivyd, Inc. remains a Hold rating as it advances its monoclonal antibody pipeline, notably VYD2311 as a Covid-19 vaccine alternative. VYD2311 offers broader patient coverage and intramuscular dosing, with phase 3 DECLARATION and LIBERTY trials set to begin by end of 2025; Topline data mid-2026. Company's technology shows strong variant-neutralization, and expansion into RSV and measles preven...